HoFH: New insights in prevalence and therapy
Dr. Kees Hovingh, Amsterdam, NL, shares some new insights in the prevalence of Homozygous and Heterozygous Familial Hypercholesterolemia and novel therapeutic options to lower LDL-c in this patient population
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: